Isomorphic Labs: Alphabet's AI drug design arm
First AI-designed drugs are expected to enter clinical trials in 2026, according to Hassabis at Davos. Its drug design engine, released in Feb 2026, has twice the performance of AlphaFold 3. It is private and wholly owned by Alphabet, so it is not directly investable.
Read the brief